Vera Health Raises $28.5M Series A for Clinical AI Search

Vera Health has closed a $28.5 million Series A round to expand its clinical AI search engine, lifting total funding to $32 million, executives said in the Oct. 27 announcement.

Threshold Ventures led the round. Optum Ventures, Mantis VC and SV Angel participated. Existing investors Y Combinator and Gradient tripled their positions.

The startup's pitch is simple: show clinicians the evidence before the answer. The platform scans more than 60 million peer-reviewed publications, clinical guidelines, consensus statements and drug labels, according to executives.

What makes Vera different from general AI tools?

Co-founder Taieb Bennani built the product around four principles: honesty, traceability, transparency and context. Honesty comes first, he said.

"The first, and for me the most important, is honesty," Bennani told Fierce Healthcare. "Language models are built to sound certain; medicine rarely is. A general-purpose model produces plausible sentences, but medicine requires verifiable ones. So we built Vera the other way around: it finds the evidence first, and only then writes the answer. In essence, it's a search engine that reasons like a clinician."

Threshold's Emily Melton framed the investment the same way.

"Vera is compelling because it starts with the evidence, not just an answer—helping clinicians find and assess the research behind a decision while making its strengths and limitations visible," said Melton, co-founder and managing partner at Threshold Ventures. "By bringing that evidence to the point of care, Vera becomes a trusted clinical intelligence layer, not just another AI tool."

How fast is the company growing?

Vera now serves more than 800,000 clinicians across 190 countries. A year ago, the figure stood at "a few thousand," Bennani said.

The company reached that scale with almost no sales machinery. Bennani said most users found Vera through a colleague, not a marketing campaign.

"Most found Vera through another clinician, a colleague down the hall, rather than through a large sales operation," Bennani said. "Every month since June, Vera has been the most downloaded clinical app in the world across the App Store and Google Play. In September, it was downloaded more times than several of the biggest players in our space combined, companies worth 100 times or more what we've raised."

The team itself stayed lean. Vera doubled from six to 12 people while crossing 800,000 users.

"That's the clearest sign we're solving a real problem," Bennani said. "Clinicians don't come back to a tool every day unless it earns their trust. And the need is the same everywhere: across countries, specialties and health systems."

Why does the 17-year gap matter?

The startup's mission rests on a well-known research finding. New medical knowledge takes an estimated 17 years to reach clinical practice, according to research cited by Bennani from the Journal of the Royal Society of Medicine.

"Our mission is to close the gap between what medicine knows and what every patient receives," Bennani said. "Today, that gap is measured in years. We want it measured in seconds."

That gap is the market. If a search engine can compress a 17-year lag into a lookup at the point of care, the product sells itself to hospitals and individual clinicians alike.

Where will the $28.5 million go?

The capital funds four areas, Bennani said:

• further investment in evidence infrastructure
• international expansion
• partnerships
• hiring

The company is now recruiting internationally, placing staff close to the clinicians and health systems it serves.

"Vera is what it is because of the people who build it, and we love how much a small team can achieve," Bennani said. "We'll grow, but we'll stay focused and obsessed with the product."

How crowded is this market?

Competition has intensified on every flank. Established clinical reference players Elsevier, with ClinicalKey, and Wolters Kluwer, with UpToDate, now face AI-native rivals OpenEvidence and Doximity Ask. Consumer tech giants OpenAI and Anthropic are circling the same territory.

Vera's answer is distribution and trust: a clinician-to-clinician growth loop and download numbers that, by Bennani's account, outpaced far larger competitors in September. The Series A buys the infrastructure to keep that lead while incumbents and AI labs push into clinical search.